Search

Background Myelosuppressive chemotherapy-induced febrile neutropenia (FN) is a life-threatening condition. Patients receiving granulocyte colony-stimulating factors (G-CSF) have shorter duration of neutropenia, faster recovery from fever, and shorter duration of antibiotics use. Most strategies for FN prevention using daily G-CSF and pegfilgrastim are based on overseas studies. Data on Japanese patients were lacking; thus, we previously determined the incidence of FN in non-Hodgkin B cell lymphoma (B-NHL) patients at our center. Here, we aimed to gain additional insights into pegfilgrastim use in this population. Methods This single-center, retrospective, observational study (STOP FN in NHL 2) enrolled patients with B-NHL who underwent a regimen comprising rituximab and CHOP therapy over a 2-year period (January 2015–June 2017). The incidence of FN in cycle 1 of chemotherapy, risk factors for FN development, and use of daily G-CSF and pegfilgrastim were evaluated. Results We evaluated 239 patients: 61 patients did not receive G-CSF and 178 received G-CSF. The incidence of FN was 10.5% (95% confidence interval [CI] 6.9–15.1%) in cycle 1 and 13.0% (95% CI 9.0–17.9%) in all cycles. The FN incidence was significantly lower (P = 0.0008) in patients receiving daily G-CSF and pegfilgrastim than patients not receiving G-CSF. Significant risk factors for FN were age ≥ 65 years, albumin

PURPOSE This study evaluated the precision of electronic working length by microcomputed tomography using two electronic apex locators (EALs). METHODS Twenty single-rooted permanent teeth without caries or restorations were selected as the subject teeth. The positions of the minor apical constriction (AC) and major apical foramen (AF) were measured by electronic root canal length, and microcomputed tomography was performed with the file inserted and fixed in the root canal. All teeth were measured individually and independently by two operators. The Mann-Whitney U-test was used to statistically test the AC and AF values using two EALs; P < 0.05 was defined as statistically significant. RESULTS This was 65.0% within 1.5 mm in the case of two EALs on AC. This was more than 90.0% within 1.0 mm in the case of two EALs on AF. Comparison of the differences between the respective AC and AF of the measurements obtained using the two EALs revealed no significant difference. CONCLUSION The two EALs are devices that can greatly improve the accuracy of WL control.

Allograft inflammatory factor-1 (AIF-1) is a marker for activated microglia. Unilateral common carotid artery occlusion (UCCAO) was conducted to elucidate mechanisms that regulate AIF-1 expression in C57BL/6 male mice. Immunohistochemical reactivity of microglia against anti-AIF-1 antibody was increased significantly in the brain of this model. The increased AIF-1 production was further confirmed by ELISA using brain homogenate. Real-time PCR demonstrated that the increased AIF-1 production was regulated at the transcriptional level. Serum AIF-1 levels were further examined by ELISA and marked increase was observed on Day 1 of UCCAO. To examine the influence of AIF-1, immunohistochemical staining was performed and revealed that the immunoreactivity against anti-Iba-1 antibody was significantly increased in various organs. Among them, the accumulation of Iba-1+ cells were observed prominently in the spleen. Intraperitoneal injection of minocycline, a potent microglia inhibitor, reduced the number of Iba-1+ cells suggesting microglia activation-dependent accumulation. Based on these results, AIF-1 expression was further examined in the murine microglia cell line MG6. AIF-1 mRNA expression and secretion were up-regulated when the cells were cultured under hypoxic condition. Importantly, stimulation of the cells with recombinant AIF-1 induced the expression of AIF-1 mRNA. These results suggest that increased AIF-1 production by microglia in cerebral ischemia regulate the AIF-1 mRNA expression at least in part by an autocrine manner.

Proteasome inhibitor MG132 was shown to enhance the secretion of interleukin 8 (IL-8) by various cells. The enhancement is regulated by the transcription factor activator protein-1 (AP-1) at the transcriptional level. AP-1 is a dimer formed by AP-1 family proteins. The purpose of the present study was to explore the combinations of the AP-1 family proteins that contribute to MG132-driven IL-8 secretion. Oral squamous cell carcinoma-derived cell lines, Ca9-22 and HSC3, were used to demonstrate their response to MG132. IL-8 secretion was augmented by MG132 in both cell lines. c-Jun expression was detected in both the cell lines, whereas c-Fos expression was detected only in the HSC3. The influence of MG132 stimulation on c-Jun and c-Fos expression was further examined by western blot analysis. c-Jun expression was increased by MG132 stimulation, whereas c-Fos expression was not detected even after MG132 stimulation. As JunB is reported to inhibit the transcriptional activity of the AP-1 complex, we speculated that the c-Jun homodimer should contribute to IL-8 enhancement. Expression vectors encoding wild type and c-Jun mutants, M17 and M22-23, respectively, were constructed and transfected into the Ca9-22 cells. In contrast to our expectations, MG132-induced IL-8 secretion was significantly reduced in all the transfectants suggesting that other c-Jun members might form homodimers with c-Jun and contribute to IL-8 enhancement. Transfection of the cells with c-Jun or JunB small hairpin RNA (shRNA) reduced IL-8 secretion up to 50% and 65% of the control shRNA transfectant. Furthermore, cotransfection of both shRNA almost completely inhibited the IL-8 secretion. These results indicate that JunB not only inhibits but also enhances the transcription of c-Jun targets in combination with c-Jun.

Introduction; The prognosis of relapsed and refractory DLBCL (RR-DLBCL) after R-CHOP therapy is poor and the more than half of these cases had no cure. Autologous peripheral blood stem cell transplantation (auto-PBSCT) raises the survival rate about 20%, however many patients cannot reach the transplantation. The poor prognostic factors in RR-DLBCL have not been cleared yet. MYC/IgH translocations induced poor prognosis of DLBCL, especially double hit DLBCL is independent category in WHO 2016 criteria. However, in RR-DLBCL, the impact of MYC/IgH translocation had not been cleared yet. In this study, we studied the expression of MYC/IgH translocation in RR-DLBCL cases and analyzed the relationships with the prognosis by retrospectively. Methods; We studied the translocations of MYC and BCL-2 by FISH analysis RR-DLBCL cases from 2006 to May 2017 in our institute. The cells were obtained from the biopsy samples at the first diagnosis and relapse or refractory status. The cells have been fixed by carnoy solution. After hybridizing with each probe, the 100 cells or more were analyzed by In Cell Analyzer 6000 and the positive levels were determined as 5% or more in both MYC and BCL-2. Additionally pathological review and clinical status were studied among these cases, retrospectively. All cases are treated by R-CHOP at diagnosis and followed by salvage therapy after relapse with or without auto-PBSCT. This study protocol was approved in our institutional ethical review board. Results; Within 46 RR-DLBCL, 24 cases were negative for MYC translocation and 22 were positive. All MYC-positive cases were translocated with IgH except one case and the 9 cases (47.8%) were BCL2-positive. The median age was 62.4 (40-83) in MYC-negative and 62.6 (44-82) in MYC-positive cases. GC type was 11 (45%) and 9 (40.9%), and High IPI cases were 8 (33.3%) and 12 (54.5%) in MYC-negative and positive cases respectively. In these RR-DLBCL, the 5-year Overall survival (OS) was inferior in MYC-positive group (79.4%, 95% CI; 53.5-91.8%) compared to MYC-negative group (56.2%, 95%CI; 32.1-74.7%) (P=0.0414). There was no significant difference in progression free survival (PFS). There were no statistically significant differences in overall response rate (ORR), OS and PFS after second therapy between MYC-positive and negative group. The death cases were 6 (25%) and 11 (50%), respectively (P=0.079). By the pathological analysis, the transformed DLBCL cases from follicular or indolent lymphoma were significantly more in MYC negative group (12; 50%) than in MYC positive group (4; 18.1%) (P=0.024). In the transformed DLBCL, at the first relapse, 2nd biopsy detected heterogeneous pattern, such as the only indolent lymphoma, DLBCL or contamination of both type. In such cases, at the 2nd relapse, the pathological diagnoses had changed again. OS and PFS were significant superior in transformed DLBCL than de-novo DLBCL after second therapy. 2-year OS were 59.0%(95%CI 37.9-75.1%) and 92.9%(59.1-99.0%) (P=0.00474) and PFS were 16.13 and 49.43 moths (95% CI was 10.4 to 20.1 months and 16.1 to 63.7 months; P=0.00063), in transformed FL and de novo-DLBCL, respectively. The multivariate analysis identified transformed DLBCL as independent prognostic factor for both PFS and OS. Also, in MYC positive group, transformed DLBCL cases were superior to de-novo DLBCL for both OS (17.5 months vs. not yet reached, P=0.0353) and PFS (13.3 vs. 63.3moths, P= 0.0353) respectively. Discussion and conclusion; From our results, it was suggested MYC-positive is still poor prognostic factor of overall survival in RR-DLBCL. However, RR-DLBCL contaminated transformed DLBCL especially in the MYC-negative group. After 2nd therapy, the transformed DLBCL were related to good prognoses compared to de-novo-DLBCL, in also MYC-positive group. We can consider that treatment strategy of transformed DLBCL were should be separated from de-novo DLBCL at the relapse, then MYC-positive transformed DLBCL still possesses for indolent character. Disclosures Mishima: Chugai pharmaceutical inc, Roche: Other: commissioned work. Yokoyama:Chugai pharmaceutical inc, Roche: Other: commissioned work. Nishimura:Chugai pharmaceutical inc, Roche: Other: commissioned work. Terui:Celgene: Honoraria; Janssen Pharmaceutical KK: Honoraria; Takeda pharmaceutical: Honoraria; Novartis pharma: Honoraria; Bristol myers Squib: Honoraria.

The transformation of indolent lymphoma is biologic event leading to aggressive lymphoma status. As same de-novo diffuse large B cell lymphoma (DLBCL), the outcome of DLBCL with transformation has improved by the use of rituximab contained therapy. However, the effects of rituximab maintenance for DLBCL with transformation remain unknown. We performed a retrospective analysis to evaluate the efficacy of rituximab maintenance for DLBCL with transformation. We studied patients newly diagnosed as transformed DLBCL from March 2005 to November 2017 in our institution. The pathological diagnosis was performed based on morphological and immunohistochemical analyses. Transformed DLBCL was defined in our study as a coexistence with components of follicular lymphoma (FL) or MALT lymphoma and DLBCL in a biopsied tissue at the diagnosis. Almost all patients were treated with R-CHOP chemotherapy (2 were treated by radiation with or without rituximab therapy, one was R-ICE chemotherapy). 15 patients received rituximab maintenance therapy for two years after achieving good PR or more by first therapy. PET-CT was used to evaluate the stage at the diagnosis and the response after therapy. The statistical analyses of characteristics of patients were performed by Fisher's exact test. The survivals were calculated by the Kaplan Meier method, and statistical analysis were performed by log rank test. Factors affecting OS and PFS were evaluated using Cox proportional hazard model. We analyzed 52 transformed patients. Median age was 64 years old (range 43-87), 35 patients were male (67%) and 17 were female (33%), 44 (84%) were transformed from FL and 8 (16%) were from MALT lymphoma. Germinal center B cell (GCB) type were 35 (67%) and activated B cell (ABC) were 16 (30%). An ECOG performance status (PS) ≧2 was only 1 patient (1.9%). 3 (5.7%) had B symptoms, 16 (30%) had LDH ≧ULN, 28 (53%) had stage of Ⅲ or Ⅳ, 5 (9.6%) had bone marrow invasion, 13 (25%) had IPI score ≧3, and 26 (50%) had one or more extranodal diseases. There were no significant differences in characteristics between rituximab maintenance group and no maintenance group. After induction therapy, CR was achieved in 48 (92%) and PR was 4 (8%). With a median follow up of 66 months (range 7-143), 5-year OS and 5-year PFS were 95.6% (range 83.3-98.9) and 71.7% (range 55.4-83.0) respectively. There were not statistically significant in OS and PFS between the rituximab maintenance group and the observation group (5-year OS: 100% vs 93.6%, p=0.0895, 5-year PFS: 100% vs 65.7%, p=0.0792). However, subgroup analyses showed that rituximab maintenance group was significantly superior to no maintenance group in PFS in the cases of stage III or more (5-year PFS 100% vs 30.7%, p=0.0137), males (100% vs 56.7%, p=0.0436), and GCB type (100% vs 60.0%, p=0.029). The rituximab maintenance (P=0.0356: HR 0.20; 95% CI 0.046-0.899) was indicated as the clinical parameters related to PFS by multivariate analysis. Generally, DLBCL with transformation have poor prognosis. There are several previous reports about rituximab maintenance for patients with aggressive B-cell lymphoma, which concluded that rituximab maintenance in first remission didn't provide an advantage to OS and PFS. NHL 13 trial demonstrated statistical benefit of rituximab maintenance for males and low IPI group. Regard to transformed lymphoma, the study for maintenance of rituximab was really few. Hany R et al reported the outcome of patients with transformation that rituximab maintenance post R-CHOP and the number of maintenance rituximab cycles were associated with better PFS. Our data provided that rituximab maintenance was effective in transformed DLBCL with regard to prolonged PFS in subgroups of progressive stage, men, and GCB. In conclusion, from our study it was suggested that rituximab maintenance therapy have possible to improve outcomes for DLBCL with transformation. Disclosures Mishima: Chugai pharmaceutical inc, Roche: Other: commissioned work. Yokoyama:Chugai pharmaceutical inc, Roche: Other: commissioned work. Nishimura:Chugai pharmaceutical inc, Roche: Other: commissioned work. Terui:Takeda pharmaceutical: Honoraria; Janssen Pharmaceutical KK: Honoraria; Celgene: Honoraria; Bristol myers Squib: Honoraria; Novartis pharma: Honoraria.

Background: In patients with diffuse large B-cell lymphoma (DLBCL), adequate follow-up is required with the improvement of prognosis. The efficacy of scheduled imaging for patients with DLBCL who achieved complete response (CR) is discussed. The possibility to avoid surveillance imaging have been reported, although most studies are based on a small number of cases. The NCCN guideline version 4.2018 recommend not to perform scheduled imaging routinely for follow-up, or only for patients with stage III/IV. However, there is no strong evidence of supporting the inferiority of scheduled imaging. It is possible that some patients might benefit from scheduled imaging. Methods: We investigated patients with de novo DLBCL who were diagnosed in The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan from 5 January 2013 to 31 May 2016 retrospectively, to conduct a sampling of first relapsed patients after CR. Patients who achieved CR after salvage therapies were included. Patients who received first-line therapy without rituximab because of non-approved use at the time were excluded. Relapse diagnosis without pathological proof were permitted. Eligible patients had a minimum of 2 years follow-up. All data were updated 17 July 2018. Overall survival (OS) was censored at the last date of follow-up. Relapsed patients were divided into 2 groups according to a momentum of diagnosis, clinical symptoms (symptom group) or scheduled imaging (imaging group). Clinical symptoms are defined as subjective complaint, physical exam finding and blood test abnormality. Imaging modality includes echography, computed tomography (CT), magnetic resonance imaging and positron emission tomography/CT. The Hans classifier, using CD10, BCL6, and MUM1 immunohistochemistry, was used to categorize as germinal center B-cell-like (GCB) or non-GCB. Fischer's test was used for comparative between the symptom group and imaging group, Kaplan-Meier test for calculate survivals, the logrank test for statistical analysis of OS, event-free survival (EFS) and survival parameters. All statistical analyses were performed with EZR software. Results: A total of 759 patients were identified as de novo DLBCL. Then 630 achieved CR, 527 had maintained CR and 103 relapsed. Among the 103 cases, 7 patients were excluded because of lack of some data. Eventually, 96 patients with first relapse were enrolled in this analysis. Relapse was confirmed pathologically in 85% (82/96) cases. Only in the symptom group, all 7 cases were not received biopsy because of central nervous system involvement. Most patients were scheduled to perform imaging every 6 months. We divided the 96 first relapsed patients into 2 groups by the momentum of relapse diagnosis. The median follow-up duration was 56.1 months. While 67% were detected by clinical symptoms, 33% had relapse diagnosis by scheduled imaging, and their characteristics are summarized in Table 1. Significant differences in the outcome were not found between the symptom group and the imaging group: 4-year OS (57%, 95% confidence interval [CI] 0.44-0.68 vs. 4-year OS: 63%, 95% CI 0.44-0.78; P = 0.517), 4-year EFS (20%, 95% CI 0.12-0.31 vs. 28%, 95% CI 0.14-0.44; P = 0.163), and median OS after first relapse (33.0 months vs. 55.4 months; P = 0.512), respectively (Fig 1). In the symptom group, indications were lymph node swelling (38%), neurological symptoms (20%), subcutaneous mass (17%), head and neck discomfort (10%), B symptom (6%) and blood test abnormality (3%). Univariate analysis revealed that only the existence of B symptoms at first diagnosis was significant for OS (P = 0.0361). Multivariate analysis using stepwise multiple logistic regression also demonstrated that the existence of B symptoms at first diagnosis to be the single independent factor of OS (P = 0.0402). In the imaging group, univariate analysis revealed that the existence of B symptoms at first diagnosis was significant for OS (P = 0.0241). There was no significant difference in OS between patients with stage I/II and stage III/IV in the 96 relapsed patients (P = 0.618). Conclusion: These results indicate that routine image surveillance in DLBCL patients during their first CR does not improve OS and EFS. However, B symptoms at first diagnosis was a significant factor for OS in both the symptom and imaging group, Patients with B symptoms at diagnosis might receive a benefit of image surveillance. Disclosures Nishimura: Chugai pharmaceutical inc, Roche: Other: commissioned work. Mishima:Chugai pharmaceutical inc, Roche: Other: commissioned work. Yokoyama:Chugai pharmaceutical inc, Roche: Other: commissioned work. Terui:Celgene: Honoraria; Bristol myers Squib: Honoraria; Janssen Pharmaceutical KK: Honoraria; Takeda pharmaceutical: Honoraria; Novartis pharma: Honoraria.

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL). Typically, the dose of rituximab is 375 mg/m2; data obtained from recent clinical trials about the pharmacokinetics of rituximab showed that elderly women have a better outcome than elderly men and a more favorable pharmacokinetics of rituximab than all other patients with DLBCL. Therefore, optimization of the dose and schedule of rituximab is required for the subpopulation of patients with DLBCL that show a fast clearance of rituximab. The metabolism of rituximab, which is mostly excreted through the kidneys, is not completely understood thus far. Renal function, which is determined using creatinine clearance (CCr), at the time of administration may affect the clearance of rituximab, and thus, the therapeutic outcomes. We examined the association between the rate of CCr and survival outcome in patients with DLBCL treated with R-CHOP. We evaluated 653 patients with newly diagnosed de novo DLBCL, excluding those with transformed DLBCL, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from January 2005 to December 2015. All patients were treated with R-CHOP or modified regimens. CCr was calculated using the Cockcroft-Gault formula. Tumour staging and response assessment were performed using the revised response criteria for malignant lymphoma and the International Conference on Malignant Lymphomas Imaging Working Group by using positron emission tomography-computed tomography and bone marrow biopsy. Progression-free survival (PFS) and overall survival (OS) were defined as the time from the date of initiation of R-CHOP to the date of disease progression, relapse, last follow-up, or death from lymphoma. Deaths due to reasons other than lymphoma were censored. PFS and OS were estimated using the Kaplan-Meier method, and the differences were compared using the log-rank test. The Cox proportional hazards regression models were used to identify the prognostic factors to predict the PFS and OS. A total of 653 patients with DLBCL were met the inclusion criteria, and the median follow-up for survival was 64 months. Our results showed that 133 (20.3%) patients had a CCr rate less than 60 mL/min. Patients with a low rate of CCr were older, had an advanced stage of DLBCL, extranodal disease, high levels of lactate dehydrogenase (LDH), and high proportion of non-germinal cell (GC) subtype, which are indicators of a poor prognosis. Therefore, patients with a lower rate of CCr showed poorer PFS (5-year PFS 74.2% vs. 80.8%, p = 0.13) and OS (5-year OS 77.1% vs. 86.9%, p=0.013). Further, we performed subgroup analysis according to CCr using the revised International Prognostic Index (R-IPI), which includes of age >60 years, stage III/IV disease, elevated LDH levels, performance status ≥ 2, more than one extranodal site of disease. Although all prognostic groups did not show a significant difference depending on the CCr, the groups with very good and good prognosis showed superior PFS in a low rate of CCr group than high rate of CCr group (Figure 1). The results of subgroup analysis for OS were similar to those observed for PFS. Thus, patients with very good and good prognosis determined using R-IPI may be affected by the subtle difference in the clearance of rituximab, whereas those with poor prognosis may not be affected by this difference. Results of multivariate analysis for PFS and OS showed that a low rate of CCr was not a significant prognostic factor. Thus, our results showed that although CCr may be a factor for clearance of rituximab, no significant association exists between the rate of CCr and survival. Our findings suggest that modification of the dose of rituximab depending on CCr is not recommended for improving survival. Further studies are required to establish an optimal dose and schedule of rituximab in all subgroups of patients with DLBCL. Disclosures Nishimura: Chugai Pharmaceutical Co., Ltd.: Other: commissioned work. Mishima:Chugai pharmaceutical inc, Roche: Other: commissioned work. Yokoyama:Chugai pharmaceutical inc, Roche: Other: commissioned work. Terui:Bristol myers Squib: Honoraria; Celgene: Honoraria; Janssen Pharmaceutical KK: Honoraria; Takeda pharmaceutical: Honoraria; Novartis pharma: Honoraria.

Introduction The international prognostic index (IPI) was a most common prognostic score in patients with aggressive non-Hodgkin lymphoma. Therefore, rituximab improved OS in patients with diffuse large B-cell lymphoma (DLBCL), revised IPI (R-IPI) was suggested. Although, the 5-year OS is higher than 50% in patients of high risk R-IPI. National Comprehensive Cancer Network published an enhanced IPI (NCCN-IPI) for improving risk stratification. However, NCCN-IPI didn't enough evaluate clinical and disease characteristics, for example beta-2-microglobulin (B2MG), cell of origin, albumin, soluble interleukin-2 receptor (sIL-2R). Aim of this study is to evaluate clinical and disease prognostic factor in patients with DLBCL. Methods We retrospectively analyzed 647 patients who were newly diagnosed de novo DLBCL and treated with R-CHOP in our hospital from January 2005 to December 2016. We excluded primary central nervous system lymphoma and transformed from low grade B-cell lymphoma. Median follow-up time is 58.5 months (range; 2-160 months.). We collected data of blood and imaging test before chemotherapy. The patient's baseline clinical and disease characteristics included age, Ann Arbor stage, serum albumin, bulky, B symptoms (defined as recurrent fever, night sweats, or >10% weight loss), B2MG, cell of origin, cluster of differentiation (CD) 5 positive, serum C-reactive protein (CRP), ECOG performance status (PS), ferritin, gender, lactate dehydrogenase (LDH), sIL-2R, monocyte, number and site of involvement extranodal. We evaluate over 60-years old, advance stage (Ann Arbor stage Ⅲ-Ⅳ) and more than PS 2. We defined the cut-off value of B2MG, CRP, ferritin, sIL-2R, monocyte and albumin by using receiver operating characteristic curves. LDH was over the upper limit of normal. Cell of origin was classified by Hans' algorithm. CD 5 was evaluated by immunohistochemistry. The univariate analyses of between factors and OS was used in univariate of log-rank test. And the multivariate analysis was used cox proportional hazards regression analysis. Results The patient's median age was 65 years old (range 17-90 years old.). The cut-off value of B2MG is ≧2.23 mg/L, CRP is ≧0.4 mg/dl, ferritin is ≦250 ng/ml, sIL2-R is ≧1000 U/mL, monocyte is ≧608 /μL and serum albumin is ≦3.4 g/dl. In the result of univariate analysis, age, stage, albumin, B symptoms, B2MG, CD5, CRP, PS, ferritin, LDH, sIL-2R, monocyte, nonGCB, the number of extranodal sites (>1) and the involvement of bonemarrow, liver, lung, muscle, skin and pancreas affected OS. In multivariate analysis, the worse prognostic factors were age (Hazard ratio (HR) 2.13, 95% confidence interval (CI) 1.27-3.57, p Albumin, B2MG and sIL-2R weren't included prognostic score of IPI, R-IPI and NCCN-IPI. In order to validate we developed prognostic score consisting of 5 factors (age, PS, B2MG, sIL-2R and albumin). And compared with NCCN-IPI in our data. We categorized patients into 4 risk groups: low (0 factor), low-intermediate (1 factor), high-intermediate (2 or 3 factors), high (4 or 5 factors). The low risk of 5-year OS was 91.5%, low-intermediate risk was 86.2%, high-intermediate risk was 72.3% and high risk was 37.4%. The low risk of NCCN-IPI was 95.1%, low-intermediate was 86.2%, high-intermediate was 68.8% and high was 50.6%. The absolute difference in the 5-year OS between low and high risk groups was 54.1% with our study prognostic score compared with 44.5% with NCCN-IPI in our study. Conclusions Our study suggest that B2MG, sIL-2R and serum albumin are significant prognostic factors in patients with DLBCL in the rituximab era. Figure. Figure. Disclosures Yokoyama: Chugai pharmaceutical inc, Roche: Other: commissioned work. Mishima:Chugai pharmaceutical inc, Roche: Other: commissioned work. Nishimura:Chugai pharmaceutical inc, Roche: Other: commissioned work. Terui:Novartis pharma: Honoraria; Takeda pharmaceutical: Honoraria; Janssen Pharmaceutical KK: Honoraria; Celgene: Honoraria; Bristol myers Squib: Honoraria.